Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR247799 on Endothelial Function in T2DM
NCT03462017Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR247799 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change in Flow Mediated Dilation. Started Mar 2018; status: completed.
02
Drugs
SAR247799
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03462017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462017.